Cellular MR imaging of the liver using contrast agents

Molecular and Cellular MR Imaging

Volumn , Issue , 2007, Pages 247-257

  Balci, N Cem ^a   Erturk, Sukru Mehmet ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62549128873     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (54)

1. Liver anatomy and physiology, in Merck Manual, 17th ed., Beers, M.H. and Berkow, R., Eds., Wiley, New York, 1999, chap. 36.
2. Knell, A.J., Liver function and failure: the evolution of liver physiology, J R Coll Physicians Lond, 14, 205–208, 1980.
3. Read, A.E., Clinical physiology of the liver, Br J Anaesth, 44, 910–917, 1972.
4. Corless, J.K. and Middleton, H.M., III, Normal liver function. A basis for understanding hepatic disease, Arch Intern Med, 143, 2291–2294, 1983.
5. Hyslop, W.B. and Semelka, R.C., Future directions in body magnetic resonance imaging, Top Magn Reson Imaging, 16, 3–14, 2005.
6. Shoenut, J.P., Semelka, R.C., Levi, C., and Greenberg, H., Ciliated hepatic foregut cysts: US, CT, and contrast-enhanced MR imaging, Abdom Imaging, 19, 150–152, 1994.
7. Mosetti, M.A., Leonardou, P., Motohara, T., Kanematsu, M., Armao, D., and Semelka, R.C., Autosomal dominant polycystic kidney disease: MR imaging evaluation using current techniques, J Magn Reson Imaging, 18, 210–215, 2003.
8. Semelka, R.C., Hussain, S.M., Marcos, H.B., and Woosley, J.T., Biliary hamartomas: solitary and multiple lesions shown on current MR techniques including gadolinium enhancement, J Magn Reson Imaging, 10, 196–201, 1999.
9. Palacios, E., Shannon, M., Solomon, C., and Guzman, M., Biliary cystadenoma: ultrasound, CT, and MRI, Gastrointest Radiol, 15, 313–316, 1990.
10. Semelka, R.C. and Sofka, C.M., Hepatic hemangiomas, Magn Reson Imaging Clin North Am, 5, 241–253, 1997.
11. Paulson, E.K., McClellan, J.S., Washington, K., Spritzer, C.E., Meyers, W.C., and Baker, M.E., Hepatic adenoma: MR characteristics and correlation with pathologic findings, Am J Roentgenol, 163, 113, 1994.
12. Mortelè, K.J., Praet, M., Van Vlierberghe, H., Kunnen, M., and Ros, P.R., CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation, Am J Roentgenol, 175, 687, 2000.
13. Semelka, R.C., Shoenut, J.P., Ascher, S.M., Kroeker, M.A., Greenberg, H.M., Yaffe, C.S., and Micflikier, A.B., Solitary hepatic metastasis: comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences, J Magn Reson Imaging, 4, 319–323, 1994.
14. Kelekis, N.L., Semelka, R.C., Worawattanakul, S., de Lange, E.E., Ascher, S.M., Ahn, I.O., Reinhold, C., Remer, E.M., Brown, J.J., Bis, K.G., Woosley, J.T., and Mitchell, D.G., Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images, Am J Roentgenol, 170, 1005–1013, 1998.
15. Hussain, S.M., Semelka, R.C., and Mitchell, D.G., MR imaging of hepatocellular carcinoma, Magn Reson Imaging Clin North Am, 10, 31–52, 2002.
16. Hamrick-Turner, J., Abbitt, P.L., and Ros, P.R., Intrahepatic cholangiocarcinoma: MR appearance, Am J Roentgenol, 158, 77–79, 1992.
17. Delikatny, E.J. and Poptani, H., MR techniques for in vivo molecular and cellular imaging, Radiol Clin North Am, 43, 205–220, 2005.
18. Modo, M., Hoehn, M., and Bulte, J.W., Cellular MR imaging, Mol Imaging, 4, 143–164, 2005.
19. Bulte, J.W. and Kraitchman, D.L., Iron oxide MR contrast agents for molecular and cellular imaging, NMR Biomed, 17, 484–499, 2004.
20. Balci, N.C. and Semelka, R.C., Contrast agents for MR imaging of the liver, Radiol Clin North Am, 43, 887–898, 2005.
21. Semelka, R.C. and Helmberger, T.K., Contrast agents for MR imaging of the liver, Radiology, 218, 27–38, 2001.
22. Hamm, B., Mahfouz, A.E., Taupitz, M., Mitchell, D.G., Nelson, R., Halpern, E., Speidel, A., Wolf, K.J., and Saini, S., Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology, 202, 677–682, 1997.
23. Reimer, P., Schneider, G., and Schima, W., Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications, Eur Radiol, 14, 559–578, 2004.
24. Wang, C., Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas, Acta Radiol Suppl, 415, 1–31, 1998.
25. Wang, C., Ahlstrom, H., and Ekholm, S., Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study, Acta Radiol, 38, 643, 1997.
26. Aicher, K.P., Laniado, M., Kopp, A.F., Gronewaller, E., Duda, S.H., and Claussen, C.D., Mn-DPDPenhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients, J Magn Reson Imaging, 3, 731–737, 1993.
27. Bartolozzi, C., Donati, F., Cioni, D., Crocetti, L., and Lencioni, R., MnDPDP-enhanced MRI vs. dualphase spiral CT in the detection of hepatocellular carcinoma in cirrhosis, Eur Radiol, 10, 1697–1702, 2000.
28. Marti-Bonmati, L., Fog, A.F., de Beeck, B.O., Kane, P., and Fagertun, H., Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis, Eur Radiol, 13, 1685–1692, 2003.
29. Weinmann, H.J., Tissue-specific MR contrast agents, Eur J Radiol, 46, 33, 2003.
30. de Haen, C., Lorusso, V., and Tirone, P., Hepatic transport of gadobenate dimeglumine in TR-rats, Acad Radiol, 3 (Suppl 2), S452–S454, 1996.
31. Kirchin, M.A., Pirovano, G.P., and Spinazzi, A., Gadobenate dimeglumine (Gd-BOPTA). An overview, Invest Radiol, 33, 798–809, 1998.
32. Spinazzi, A., Lorusso, V., Pirovano, G., and Kirchin, M., Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers, Acad Radiol, 6, 282–291, 1999.
33. de Haen, C. and Gozzini, L., Soluble-type hepatobiliary contrast agents for MR imaging, J Magn Reson Imaging, 3, 179–186, 1993.
34. Schima, W., Petersein, J., Hahn, P.F., Harisinghani, M., Halpern, E., and Saini, S., Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir, J Magn Reson Imaging, 7, 130, 1997.
35. de Haen, C., La Ferla, R., and Maggioni, F., Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals, J Comput Assist Tomogr, 23 (Suppl 1), S169–S179, 1999.
36. Cavagna, F.M., Maggioni, F., Castelli, P.M., Dapra, M., Imperatori, L.G., Lorusso, V., and Jenkins, B.G., Gadolinium chelates with weak binding to serum proteins. A new class of highefficiency, general purpose contrast agents for magnetic resonance imaging, Invest Radiol, 32, 780–796, 1997.
37. Schuhmann-Giampieri, G., Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging, Invest Radiol, 28, 753–761, 1993.
38. Spinazzi, A., Lorusso, V., Pirovano, G., Taroni, P., Kirchin, M., and Davies, A., Multihance clinical pharmacology: biodistribution and MR enhancement of the liver, Acad Radiol, 5 (Suppl 1), S86–S89, 1998; discussion, S93–S94.
39. Kuwatsuru, R., Kadoya, M., Ohtomo, K., Tanimoto, A., Hirohashi, S., Murakami, T., Tanaka, Y., Yoshikawa, K., and Katayama, H., Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors, Invest Radiol, 36, 632–641, 2001.
40. Petersein, J., Spinazzi, A., Giovagnoni, A., Soyer, P., Terrier, F., Lencioni, R., Bartolozzi, C., Grazioli, L., Chiesa, A., Manfredi, R., Marano, P., Van Persijn Van Meerten, E.L., Bloem, J.L., Petre, C., Marchal, G., Greco, A., McNamara, M.T., Heuck, A., Reiser, M., Laniado, M., Claussen, C., Daldrup, H.E., Rummeny, E., Kirchin, M.A., Pirovano, G., and Hamm, B., Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging — a multicenter phase III clinical study, Radiology, 215, 727–736, 2000.
41. Schneider, G., Maas, R., Schultze Kool, L., Rummeny, E., Gehl, H.B., Lodemann, K.P., and Kirchin, M.A., Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison, Invest Radiol, 38, 85–94, 2003.
42. Morana, G., Grazioli, L., Schneider, G., Testoni, M., Menni, K., Chiesa, A., and Procacci, C., Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA, Acad Radiol, 9 (Suppl 2), S476–S479, 2002.
43. Grazioli, L., Morana, G., Kirchin, M.A., Caccia, P., Romanini, L., Bondioni, M.P., Procacci, C., and Chiesa, A., MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison, J Magn Reson Imaging, 17, 593–602, 2003.
44. Weinmann, H.J., Schuhmann-Giampieri, G., Schmitt-Willich, H., Vogler, H., Frenzel, T., and Gries, H., A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI, Magn Reson Med, 22, 233–237, 1991; discussion, 242.
45. Schuhmann-Giampieri, G., Schmitt-Willich, H., Press, W.R., Negishi, C., Weinmann, H.J., and Speck, U., Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system, Radiology, 183, 59–64, 1992.
46. Huppertz, A., Balzer, T., Blakeborough, A., Breuer, J., Giovagnoni, A., Heinz-Peer, G., Laniado, M., Manfredi, R.M., Mathieu, D.G., Mueller, D., Reimer, P., Robinson, P.J., Strotzer, M., Taupitz, M., and Vogl, T.J., Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings, Radiology, 230, 266–275, 2004.
47. Bellin, M.F., Zaim, S., Auberton, E., Sarfati, G., Duron, J.J., Khayat, D., and Grellet, J., Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging, Radiology, 193, 657–663, 1994.
48. Winter, T.C., III, Freeny, P.C., Nghiem, H.V., Mack, L.A., Patten, R.M., Thomas, C.R., Jr., and Elliott, S., MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions, Am J Roentgenol, 161, 1191–1198, 1993.
49. Weissleder, R., Elizondo, G., Wittenberg, J., Rabito, C.A., Bengele, H.H., and Josephson, L., Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging, Radiology, 175, 489–493, 1990.
50. Unger, E., Cardenas, D., Zerella, A., Fajardo, L.L., and Tilcock, C., Biodistribution and clearance of liposomal gadolinium-DTPA, Invest Radiol, 25, 638–644, 1990.
51. Tilcock, C., Ahkong, Q.F., Koenig, S.H., Brown, R.D., III, Davis, M., and Kabalka, G., The design of liposomal paramagnetic MR agents: effect of vesicle size upon the relaxivity of surface-incorporated lipophilic chelates, Magn Reson Med, 27, 44–51, 1992.
52. Kim, S.K., Pohost, G.M., and Elgavish, G.A., Gadolinium complexes of [(myristoyloxy)propyl]diethylenetriaminetetraacetate: new lipophilic, fatty acyl conjugated NMR contrast agents, Bioconjug Chem, 3, 20–26, 1992.
53. Kobayashi, H. and Brechbiel, M.W., Nano-sized MRI contrast agents with dendrimer cores, Adv Drug Deliv Rev, 57, 2271–2286, 2005.
54. Kobayashi, H., Saga, T., Kawamoto, S., Sato, N., Hiraga, A., Ishimori, T., Konishi, J., Togashi, K., and Brechbiel, M.W., Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64), Cancer Res, 61, 4966–4970, 2001.